Research & Development

Antikor Biopharma and Essex Bio-Technology forge strategic alliance in FDC for cancer treatment

Biotechnology company Antikor Biopharma Ltd is pleased to announce that it has entered into an Investment Agreement for up to US$3,100,000 with Essex Bio-Investment, a wholly-owned subsidiary of Essex Bio-Technology Ltd (”EssexBio”), which will enable Antikor to consolidate and expand its position as a leading innovator in smaller-format conjugate therapies for solid tumours.

Kyowa Kirin buys back Tivozanib non-oncology rights from AVEO Oncology

Kyowa Kirin and AVEO Oncology announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which includes the U.S. and EU.

Exelixis, Aurigene strike deal to discover and develop novel therapies for cancer

Exelixis, Inc. announced that it has entered into an exclusive collaboration, option and license agreement with Aurigene Discovery Technologies Limited (Aurigene), the India-based discovery biotechnology company focused on oncology and inflammatory disorders.

Pfizer completes acquisition of Array Biopharma

Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.

NEC acquires Norwegian bioinformatics company, OncoImmunity

NEC Corporation announced the acquisition of OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight against cancer.

Verastem signs license deal with Sanofi for COPIKTRA in certain countries

Verastem, operating as Verastem Oncology, announced their entry into an exclusive licensing agreement with Sanofi to develop and commercialize Verastem Oncology’s COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of all oncology indications in Russia and CIS, Turkey, the Middle East and Africa.

Zambon acquires Breath Therapeutics for up to £446m

Multinational pharmaceutical firm Zambon has acquired biopharmaceutical firm Breath Therapeutics from Sofinnova Partners in a deal worth up to €500m (£446m).

Gemphire Therapeutics and NeuroBo Pharmaceuticals announce merger agreement

Gemphire Therapeutics, a clinical-stage biopharmaceutical company and NeuroBo Pharmaceuticals, a privately-held clinical-stage biotechnology company, have entered into a definitive agreement whereby NeuroBo will merge with a wholly-owned subsidiary of Gemphire in an all-stock transaction.

Ligand acquires Ab Initio Biotherapeutics, an antigen-discovery company

-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash.